Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?

American Journal of Kidney Diseases

Volumn 53, Issue 2, 2009, Pages 192-196

  Berns, Jeffrey S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; LOSARTAN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL;

ALBUMINURIA; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIALYSIS; DRUG WITHDRAWAL; EDITORIAL; HEALTH CARE PERSONNEL; HUMAN; KIDNEY DISEASE; MONOTHERAPY;

EID: 58249099298     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.11.016     Document Type: Editorial

References (25)

1. KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 suppl 1 (2004) S1-S290
2. Casas J.P., Chua W., Loukogeorgakis S., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
3. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135 (2001) 73-87
4. Jafar T.H., Stark P.C., Schmid C.H., et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60 (2001) 1131-1140
5. Strippoli G.F., Bonifati C., Craig M., et al. : Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev (2006) CD006257
6. Chrysostomou A., Pedagogos E., MacGregor L., and Becker G.J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1 (2006) 256-262
7. Wenzel U. Aldosterone and progression of renal disease. Curr Opin Nephrol Hypertens 17 (2008) 44-50
8. Bomback A.S., Kshirsagar A.V., Amamoo M.A., and Klemmer P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis 51 (2008) 199-211
9. Tylicki L., Rutkowski P., Renke M., et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis 52 (2008) 486-493
10. Catapano F., Chiodini P., De Nicola L., et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression. Am J Kidney Dis 52 (2008) 475-485
11. Jennings D.L., Kalus J.S., Coleman C.I., et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet Med 24 (2007) 486-493
12. Kunz R., Friedrich C., Wolbers M., and Mann J.F. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148 (2008) 30-48
13. MacKinnon M., Shurraw S., Akbari A., et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 48 (2006) 8-20
14. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
15. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008) 547-553
16. McMurray J.J. ACE inhibitors in cardiovascular disease-unbeatable?. N Engl J Med 358 (2008) 1615-1616
17. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
18. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362 (2003) 767-771
19. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
20. Nakao N., Yoshimura A., Morita H., et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361 (2003) 117-124
21. Kunz R., Wolbers M., Glass T., and Mann J.F. The COOPERATE trial: A letter of concern. Lancet 371 (2008) 1575-1576
22. Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol 26 (2006) 629
23. Cohen DL, Townsend RR: Is there added value to adding ARB to ACE inhibitors in the management of CKD? J Am Soc Nephrol (in press)
24. Griffin K.A., and Bidani A.K. Progression of renal disease: Renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 1 (2006) 1054-1065
25. Sarafidis P.A., and Bakris G.L. Renin-angiotensin blockade and kidney disease. Lancet 372 (2008) 511-512